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Abstract
Bone is the preferredmetastasis site of advanced prostate cancer (PCa). Using an in vivomurinemodel of humanPCa
cell metastasis to bone, we noted that the majority of animals that develop skeletal metastasis have either spinal
lesions or lesions in the bones of the hindlimb. Much less frequently, lesions develop in the bones of the forelimb.
We therefore speculated whether the environment of the forelimb bones is not permissive for the growth of PCa.
Consequently, data on tumor prevalence were normalized to account for the number of PCa cells arriving after intra-
vascular injection,marrowcellularity, and number of hematopoietic stemcell niches. None of these factorswere able
to account for the observed differences in tumor prevalence. An analysis of differential gene and protein levels iden-
tified that growth arrest specific-6 (GAS6) levels were significantly greater in the forelimb versus hindlimb bone mar-
row. When murine RM1 cells were implanted into subcutaneous spaces in immune competent animals, tumor
growth in the GAS6−/− animals was greater than in GAS6+/+ wild-type animals. In an osseous environment, the
human PC3 cell line grew significantly better in vertebral body transplants (vossicles) derived from GAS6−/− animals
than in vossicles derived from GAS6+/+ animals. Together, these data suggest that the differences in tumor preva-
lence after intravascular inoculation are a useful model to study the molecular basis of tumor dormancy. Importantly,
these data suggest that therapeuticmanipulation of GAS6 levels may prove useful as a therapy for metastatic disease.
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Introduction
Prostate cancer (PCa) is the most commonly diagnosed malignancy in
US men [1]. Bone is the preferred site of metastasis in advanced PCa
and the only clinically evident site of metastasis at the time of death
in many individuals [2]. Therefore, there is great need for the de-
velopment of therapeutic strategies that target advanced PCa and its
interactions with bone. A prerequisite for the development of new
therapeutics is an improved understanding of the fundamental mecha-
nisms that regulate the metastatic process, including dormancy and
growth of tumor cells in bone.
To study bone metastases using human tumor cells, many investi-
gators have turned to an intracardiac injection model in immunodefi-
cient animals [3]. Since the introduction of the model [4], a growing
understanding of the initial events that lead to metastases has occurred.
The identification of several homing factors [3,5,6], host and tumor-
derived factors that are essential for tumor growth in bone [7,8], has
been achieved. Hematopoietic stem cells (HSCs) “home” to the bone
marrow, as do PCa cells, and compete for occupancy of the HSC niche
[9]. One of the molecular determinants for these events, the CXC che-
mokine stromal–derived factor 1 (SDF-1 or CXCL12) and its recep-
tors, CXCR4 and CXCR7, seem to play pivotal roles in niche
competition [5,10]. Once in the marrow, tumor cells engage in cross
talk with microenvironmental cells including hematopoietic cells and
mesenchymal-derived cells, which activate signaling pathways to estab-
lish a vicious cycle of tumor growth and bone remodeling [6].
Whereas intracardiac injection of PCa cells into immune-deficient
mice has lead to significant advances in our understanding of the hom-
ing and tumor-stromal cross talk, slower progress has been made in
understanding themolecular basis of dormancy. Using the intracardiac
model, we have noted that most animals that develop skeletal metastasis
have either spinal or mandibular lesions or lesions in the bones of the
hindlimb. Rarely do lesions develop in the bones of the forelimb. We
speculated that there is something unique about these tissues that is
not permissive for tumor growth. We used the observed differences
in tumor prevalence in the forelimbs versus hindlimbs as a model to




The PC3 (CRL-1435) PCa cell line was obtained from the Ameri-
can Type Culture Collection (Rockville, MD). Intracardiac injec-
tions of luciferase-labeled PC3 cells, PC3Luc, were performed in
6- to 8-week-old male Hsd:Athymic Nude-Foxn1nu (Harlan, Haslett,
MI), CB.17. SCID, NOD.CB17-Prkdcscid/J, or NOD/SCID/IL-
2Rγnull mice ( Jackson Laboratory, Bar Harbor, ME) under 3% iso-
flurane anesthesia (Abbott Laboratories, North Chicago, IL). All the
animal experimental procedures were approved by the University of
Michigan Committee for the Use and Care of Animals. Left ventric-
ular cardiac injections were performed with 1 × 105 cells suspended in
100 μl of phosphate-buffered saline (PBS) using a 27-gauge needle.
GAS6−/− Mice
Homozygous GAS6−/− mice were originally generated by homolo-
gous recombination in the laboratory of Dr Carmeliet (University in
Leuven) as described [11]. Five- to seven-week-oldGAS6−/−mice were
used for experimental tumor growth. All experimental procedures
were approved by the University of Michigan Committee for the Use
and Care of Animals.
In Vivo Assay of GAS6−/− Effect on Subcutaneous
Tumor Development
To evaluate tumor growth, subcutaneous tumors were established.
RM1 cells (1 × 104 cells) were mixed in growth factor–reducedMatrigel
(Collagen type 1 Rat Tail; BD Biosciences, Bedford, MA). Five- to
seven-week-old male C57BL6 background wild-type (GAS6+/+) or
GAS6−/− mice were anesthetized with isoflurane inhalation. After shav-
ing and cleaning the skin, subcutaneous injections using a 25-gauge
needle were used to establish the tumors. The animals were monitored
daily, and tumor volumes were evaluated every 3 days, from day 13 to
23. Tumor volumes were calculated using the formula V = the shortest
diameter × the longest diameter × height.
Bioluminescence
Tumor incidence was evaluated by bioluminescence imaging (BLI)
4 to 6 weeks after tumor inoculation. Mice were injected intraperitone-
ally with luciferin (100 μl at 40 mg/ml in PBS) before imaging. Mice
were anesthetized with 1.5% isoflurane/air and a Xenogen IVIS (Caliper
Life Sciences, Hopkinton, MA) cryogenically cooled imaging system was
used. Bioluminescence generated by the luciferin/luciferase reaction served
as a locator for cancer growth and was used for quantification using the
LivingImage software (Caliper Life Sciences) on a red (high intensity/cell
number) to blue (low intensity/cell number) visual scale. A digital grayscale
animal imagewas acquired followed by acquisition and overlay of a pseudo-
color image representing the spatial distribution of detected photon counts
emerging from active luciferase within the animal. Signal intensity was
quantified as the sum of all detected photons within the region of interest
during a 1-minute luminescent integration time. Tumor incidence was
scored on a dichotomous scale as being either positive or negative if animals
had at least one lesion detected in either the humeri or tibial/femur region.
For evaluating of tumor growth of PCa cells in an osseous environ-
ment devoid ofGAS6, the lumbar vertebrae were isolated fromGAS6+/+
or GAS6 −/−mice 7 days after birth. The vertebrae were sectioned into
single vertebral bodies (vossicles). Severe combined immunodeficient
(SCID) mice were used as transplant recipients. Four vossicles per
mouse were implanted into subcutaneous space. Before implantation,
luciferase-labeled PC3 cells (PC3Luc ) were introduced into vossicles
(20,000 cells/10 μl of PBS). Mice were imaged at 2 weeks by BLI.
Disseminated Tumor Cell Quantification by Real-time
Polymerase Chain Reaction
The number of disseminated tumor cells (DTCs) in bone was iden-
tified using real-time polymerase chain reaction (PCR) [12]. Here, ge-
nomic DNA from the designated tissues was isolated using a DNeasy
Blood and Tissue Kit (Qiagen, Valencia, CA). Sample concentrations
were standardized in each reaction to exclude false-positive results.
Real-time PCRs were performed using 15 μl of TaqMan PCR Master
mix, 100 nM human Alu TaqMan primers (F – 5′-CAT GGT GAA
ACC CCG TCT CTA-3′, R – 5′-GCC TCA GCC TCC CGA GTA
G-3′), TaqMan probe (5′-FAM-ATT AGC CGG GCG TGG TGG
CG-TAMRA-3′) (Applied Biosystems, Foster City, CA) [13], and
2 μg of isolated tissue DNA in a total volume of 30 μl. The level of
expression was detected as an increase in fluorescence using an ABI
PRISM 7700 instrument (Applied Biosystems). The DNA levels were
expressed as relative copies (% control) normalized against murine
β-actin (catalog no. 4331182; Applied Biosystems), and a standard
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curve was constructed from serial dilutions of a purified Alu comple-
mentary DNA fragment cloned by classic PCR. Numerical data were
determined against a standard curve established using murine bone
marrow containing log-fold dilutions of human PCa cells. Positive
and negative controls included tissues obtained from non–PCa-
injected mice or DNA derived directly from PCa cells.
Flow Cytometry
For analyzing HSCs from forelimbs and hindlimbs of SCID mice,
the bone marrow cells were flushed from the humerus, femur, and
tibia. Cells were incubated first with a biotinylated anti-Lineage
(CD5, CD45R [B220], CD11b, Gr-1 [Ly- 6G/C], and Ter-119)
antibody cocktail (Miltenyi Biotec, Auburn, CA) for 10 minutes at
4°C, then rinsed and stained with an antibody cocktail of APC-anti–
stem cell antigen 1 (Sca-1) (clone D7; eBioscience, San Diego, CA),
PE/Cy7–anti–c-Kit (clone 2B8; BioLedge, San Diego, CA), PE–anti-
CD150 (clone TC15-12F12.2; BioLegend), fluorescein isothiocyanate
(FITC)–anti-CD41 (clone MWReg30; BD Biosciences), FITC–anti-
CD48 (clone BCM-1; BD Biosciences), and FITC–anti-Biotin anti-
bodies (Miltenyi Biotec) for another 30 minutes at 4°C. HSCs were
analyzed on a FACS Vantage dual laser flow cytometer (Becton
Dickinson, Franklin Lakes, NJ) by gating on cells that were
CD150+CD41−CD48− Lin−Sca-1+cKit+ (termed SLAM HSCs).
For the cell surface expression of AXL, SKY, and MER, RM1 cells
were stained with anti-mouse AXL, SKY, andMER antibodies (catalog
nos.MAB8541,MAB759, andMAB591; R&DSystems,Minneapolis,
MN) or isotype-matched IgG control for 30 minutes at 4°C, and then
stained with PE–anti-rat-IgG antibody (catalog no. F0105B; R&D
Systems) for another 30 minutes at 4°C. The cell surface expression
of AXL, SKY, and MER on RM1 cells were analyzed on a FACS
Vantage dual-laser flow cytometer (Becton Dickinson).
RNA Extraction and Real-time PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen). First-
strand complementary DNA was synthesized in a 20-μl reaction vol-
ume using 0.4 μg of total RNA. Reverse transcriptase products were
analyzed by real-time PCR in TaqMan Gene Expression Assays (Ap-
plied Biosystems). TaqMan gene expression assays were used for detec-
tion of SDF-1, Annexin II (anxa2), TGF-β1, IL15, CCL2, GAS6,
AXL, SKY, MER, and β-actin (FAM/MGB probes; Applied Bio-
systems). The second-step PCRs were run for 40 cycles (95°C for
15 seconds and 60°C for 1 minute) after an initial single cycle of
50°C for 2 minutes and 95°C for 10 minutes. The PCR product was
detected using an ABI PRISM 7700 instrument (Applied Biosystems).
RNA quantity (CR) was normalized to the housekeeping gene β-actin
control by using the formula CR = 2
(40 − Ct of sample) − (40 − Ct of control).
The threshold cycle (C t) is the cycle at which a significant increase in
fluorescence occurs.
Histology
The humeri and femora of SCIDmice that were used for immunos-
taining were fixed and then decalcified and paraffin embedded. Tissue
sections were dewaxed and rehydrated, then blocked with Image-iT
FX signal enhancer for 30 minutes, and incubated for 2 hours at room
Table 1. Prevalence of Bone Lesions after Intracardiac Injection.
Tumor Model Animal Model n No. Animals with BLI Evidence
of Bone Lesions
Tumor Prevalence (%)
Forelimb Hindlimb Forelimb Hindlimb
PC3Luc Hsd:Athymic Nude-Foxn1nu 8 1 2 13 25
PC3Luc Hsd:Athymic Nude-Foxn1nu 19 1 2 5 11
PC3Luc Hsd:Athymic Nude-Foxn1nu 11 1 2 5 9
PC3Luc Hsd:Athymic Nude-Foxn1nu 10 3 5 15 25
PC3Luc Hsd:Athymic Nude-Foxn1nu 10 1 3 10 30
PC3Luc Hsd:Athymic Nude-Foxn1nu 18 0 9 0 50
Predicted Prevalence (95% Confidence Interval) 9 (04-18) 30 (21-41)*
PC3Luc CB.17 SCID 26 0 5 0 19
PC3Luc CB.17 SCID 29 1 11 0 38
PC3Luc CB.17 SCID 54 2 16 4 30
PC3Luc CB.17 SCID 54 4 16 7 30
PC3Luc CB.17 SCID 10 0 1 0 10
PC3Luc CB.17 SCID 10 0 1 0 10
PC3Luc CB.17 SCID 19 0 4 0 21
PC3Luc CB.17 SCID 10 1 0 10 0
PC3Luc CB.17 SCID 10 1 10 10 100
PC3Luc CB.17 SCID 35 0 4 0 11
Predicted Prevalence (95% Confidence Interval) 6 (03-10) 26 (20-32)*
PC3Luc NOD/SCID 50 4 22 8 44
PC3Luc NOD/SCID 50 3 23 6 46
Predicted Prevalence (95% Confidence Interval) 7 (03-14) 45 (36-55)*
PC3Luc NOD/SCID/IL-2Rγnull 29 2 21 7 72
PC3Luc NOD/SCID/IL-2Rγnull 10 2 10 20 100
PC3Luc NOD/SCID/IL-2Rγnull 10 0 1 0 10
Predicted Prevalence (95% Confidence Interval) 10 (03-33) 55 (34-75)*
Predicted Probability of Tumor Across all Animal Models† 7 (5-10) 33 (28-38)†
Luciferase-labeled human PC3 cells (PC3Luc) were injected into the left heart ventricle of immunodeficient mice, and the development of metastases was tracked by BLI imaging up to 6 weeks. Lesions in
the forelimb (humerus, radius, and ulna) or hindlimb (femur, tibia, and fibula) regions were scored as either present or absent. Predicted prevalence, 95% confidence intervals, and associated P values
were generated from the repeated measures logistic model for forelimb and hindlimb prevalence.
*Compare forelimb and hindlimb prevalence within animal model, P < .05.
†Overall test of prevalence of tumor compared between forelimb and hindlimb, P < .0001.
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temperature in the dark with 10 μg/ml primary antibodies combined
with reagents of Zenon Alexa Fluor 555(red) labeling kit. Anti-GAS6
antibody (R&D Systems, Minneapolis, MN) or rabbit polyclonal
anti–Ki-67 (Abcam) was applied to sections. The antibodies were di-
luted in PBS plus 0.2% Triton X-100. Sections were postfixed with
10% formalin for 10 minutes followed by processing with ProLong
Gold antifade reagent with 4′,6-diamidino-2-phenylindole (DAPI)
medium and covered with cover glass. Images were taken with an
Olympus FV500 confocal microscope (Olympus, Center Valley, PA).
Apoptosis was evaluated using FragEL DNA Fragmentation De-
tection Kit (Calbiochem, San Diego, CA). Here tissue slides were
deparaffinized and rehydrated and then processed following the man-
ufacturer’s instructions. After developing in 3,3′-diaminobenzidine
tetrahydrochloride solution, slides were rinsed in water and counterstained
with methyl green. Slides were then dehydrated in ethanols, dipped in
xylene, and mounted in Permount (Sigma-Aldrich, St Louis, MO).
ELISA
An antibody sandwich ELISAwas used to evaluate GAS6 expression
in the marrow from the forelimbs and hindlimbs of SCID mice and
WT mice or GAS6KO mice as a negative control by following the di-
rections of the manufacturer (catalog no. DY986; R&D Systems).
Bone marrow extracellular fluids were obtained by flushing humeri,
femora, and tibiae with 500 μl of ice-cold PBS, and the supernatant
was harvested by centrifugation at 400g for 5 minutes. GAS6 levels
were normalized to the total cell number.
Statistical Methods
A repeated-measures logistic model was used to find the predicted
probabilities of having an arm tumor or a leg tumor. Tumor prevalence
is the binary outcome, with limb type and animal model type included
as independent covariates. An unstructured correlation was used to
account for the repeated measures within the model (i.e., each mouse
has tumor incidence for the hindlimb and tumor incidence for the
forelimb in the model).
Numerical data are expressed as mean ± standard deviation unless
specified otherwise. The prevalence of tumor lesions was also evaluated
against the differences in the immunodeficiency of the animal mod-
els using a Mantel-Haenszel χ2 test. For the real-time PCR assays, a
Figure 1. Prevalence of DTCs in murine marrow and relationship to HSC niches. Luciferase-labeled human PC3 cells were injected into
the left heart ventricle of immunodeficient mice. (A) At 24 hours later, the number of PCa cells present in the bones was identified using
real-time PCR by detecting human Alu sequences and normalized with murine β-actin. Numerical data were established against a stan-
dard curve. (B) Total nucleated cells in SCID marrow. (C) Data presented in A normalized by total marrow present in each of the bones
(B). Data are presented as mean ± standard deviation. (D) HSC numbers were used to establish an indirect reflection of HSC niche num-
bers. HSCs were quantified by FACS based on the expression of the SLAM family of receptors CD150+CD48−CD41−Lin−Sca1+C-kit+).
Data are presented as mean ± standard deviation.
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Kruskal-Wallis test and Dunn multiple comparisons tests were used
with the level of significance set at P < .05.
Vossicle outcomes of bioluminescence, volume, and weight were
analyzed using generalized estimating equations to account for the
paired experimental design. The correlation structure was assumed
to be unstructured and was designed with location of vossicle nested
within the mouse. The independent covariate in the model was group
type, and comparisons were made between GAS6 KO versuswild type.
Unpaired two-tailed Student’s t tests were used for all other contin-
uous covariate analyses. The t tests and nonparametric tests were per-
formed using the GraphPad Instat statistical program (GraphPad
Software, San Diego, CA). SAS 9.3 (SAS Institute, Cary, NC) was
used for all modeling. Statistical significance was set at P < .05.
Results
Prevalence of Bone Lesions
Bone is the preferred metastatic site of advanced PCa. To create
bone metastasis, luciferase-labeled human PCa cells (PC3Luc ) were in-
jected into the left heart ventricle of immunodeficient mice, and the
metastases of these cells were followed by BLI imaging over time. In-
triguingly, we noticed that the prevalence of lesions in the long bones
was not equally distributed; with fewer lesions in the arms (humeri,
radius, and ulna) versus those observed in the hindlimb region (femur,
tibia, and fibula). To formally examine which long bones are the targets
of metastases, a retrospective examination across different experiments
and murine strains was performed in which we scored as either present
or absent animals with lesions in the forelimb or hindlimb region
(Table 1). Predicted prevalence and associated P values were generated
from the repeated measures logistic model for forelimb and hindlimb
prevalence. The prevalence of lesions identified in the hindlimb was sig-
nificantly greater than that observed in the forelimb (Table 1). These
data indicate the probability that 7% of the mice would develop a fore-
limb tumor (95% confidence interval, 5%-10%) and 33% of the
mice would develop a hindlimb tumor (95% confidence interval,
28%-38%). The predicted probability of a forearm tumor is signifi-
cantly less than that of a leg tumor (P < .0001).
Our studies were performed in immunodeficient mouse models, in-
cluding single-gene mutation models such as nude (Hsd:Athymic
Nude-Foxn1nu), severe combined immunodeficient (CB.17. SCID),
nonobese diabetic (NOD.CB17-Prkdcscid/J), and strains with targeted
deletion of IL-2Rγnull on the NOD/SCID background (NOD/SCID/
IL-2Rγnull). These models of increasing immunodeficiency afforded
the opportunity to examine differences in tumor prevalence between
the different animal models. We observed that the proportion of mice
with hindlimb lesions increases with increasing immunodeficiency of
the animal (Mantel-Haenszel χ2, P = .0018; Table 1). However, the
animal model type did not demonstrate different probabilities of
developing tumors in the forelimb.
Prevalence of DTCs
A possible reason for the noted differences in tumor prevalence be-
tween the bones of the forelimb versus those of the hindlimb may be
due to the differences in the ability of the tumor cells to traffic in the
vasculature. To explore this possibility, intracardiac injection of
PC3Luc cells was performed, and 24 hours later, the number of PCa
cells present in the bones was identified using real-time PCR.
Figure 1A demonstrates that within 24 hours, the number of DTCs
in the humerus was approximately 25% of the total found in the
femur. Because this difference could in part explain the observed dif-
ferences in tumor incidence reported in Table 1, we next normalized
the results against total nucleated marrow cells present in each of the
bones (Figure 1B). As shown in Figure 1C , when normalized to total
nucleated marrow cells, the number of DTCs in the hindlimb bones
(femur + tibia) was only 1.4-fold greater in number than that in the
humerus. Using 1.4-fold to normalize for the differences in cells arriv-
ing into the forelimb versus the hindlimb bones, the observed incidence
in osseous lesions, we would therefore expect ∼9% of the animals to
have lesions located in their arm. These data suggest that the dif-
ferences in the prevalence of tumors in the limbs of the animals are
not likely due to the differences in tumor cell trafficking or homing
to the marrow.
Prevalence of Tumors in Relationship to HSC Niches
Previously, we reported that PCametastases usurp theHSC homing
pathways to establish footholds in the marrow [5]. More recently, we
demonstrated that disseminated PCa cells directly compete withHSCs
for occupancy of the HSC niche and that increasing/decreasing niche
size alters dissemination [9]. Therefore, a second possibility that may
explain the observed tumor prevalence could be the number of avail-
able HSC niches in the humerus versus the femur. Because there is no
direct method to identify the number of niches present in any tissue,
and bone marrow transplant data suggest that only 1% to 5% of HSC
niches are unoccupied at any single time [14], we chose to examine
Figure 2. Differential gene expression between the femur and hu-
merus. Real-time PCR for establishing differential mRNA expres-
sion for selected genes in the whole bone marrow (WM) or
endosteal osteoblasts (OB) isolated by differential digestion from
the femur and humerus of SCID mice. (A) Selected gene targets
SDF-1, annexin II (anxa2), and TGF-β1. B, Data for IL15, CCL2, and
GAS6. Data were normalized to murine β-actin and are presented
as mean ± standard deviation from three independent PCRs.
*P < .05, #P < .001 between paired groups.
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HSC numbers as an indirect reflection of HSC niche numbers. Here,
FACS was used to quantify HSCs using the expression of the SLAM
family of receptors as previously demonstrated (CD150+CD48−CD41−
Lin−Sca1+C-kit+) [15]. On the basis of this analysis, it was noted that
the total number of HSCs in the humerus was ∼3.5 times larger than
in the femur (Figure 1D). Therefore, if the number of HSCs reflects the
number of HSC niches, one would expect to observe a greater prev-
alence of tumors in the forelimbs than in the hindlimbs. Based on this
analysis, it seems unlikely that the number of HSC niches alone
explains the observed differences in tumor prevalence.
Differential Gene Expression in the Forelimb
and Hindlimb Bones
Previous work from our group has demonstrated that endosteal
osteoblasts play a significant role in establishing the HSC niche
[16–19]. Moreover, it is this niche that is targeted by PCa dur-
ing metastasis [9]. To explore the molecular mechanisms in tumor
prevalence in different bones, whole bone marrow or endosteal
osteoblasts were isolated from the humeri, femora, and tibiae of SCID
mice, and real-time PCR was performed for selective gene targets. Pre-
viously, we have shown that SDF-1 serves a chemoattractant and
growth factor for PCa in bone [5,10,20–25], and annexin II (anxa2)
serves as an adhesion factor for PCa [26]. Therefore, our initial screen
included examinations for SDF-1 and anxa2. There were no differ-
ences in messenger RNA (mRNA) expression for SDF-1 or anxa2 be-
tween the whole marrow or osteoblasts isolated from the forelimb and
hindlimb bones (Figure 2A). Similarly, no differences were observed in
the expression of TGF-β1, IL15 and CCL2, which were examined
owing to their known roles in metastasis and dormancy [7,27–30]
(Figure 2, A and B). In previous studies, we reported that GAS6 inhi-
bits proliferation of PCa cell lines and provides protection from
chemotherapy [31]. In addition, GAS6 is a protein known to play a
role in suppressing HSC proliferation [32]. Surprisingly, the expres-
sion of GAS6 mRNA was significantly greater in both the whole
marrow and the osteoblast fractions isolated from the forelimb versus
those isolated from the hindlimb bones (Figure 2B ).
Figure 3. GAS6 protein levels differs between the humerus and femur. (A-L) Representative tissue samples immunostained with anti-
GAS6 antibody and counterstained with DAPI nuclear of paired samples from three mice (A-D, E-H, I-L). Original magnification, ×40
(A, C, E, G, I, K) or ×20 (B, D, F, H, J, L). Scale bar, 100 μm. (M) Levels of GAS6 in the extracellular marrow fluids were determined by
ELISA normalized by total cell numbers. Data are presented as mean ± standard deviation from triplicate determinations. *P < .05
between paired groups.
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GAS6 Expression Differences between Forelimb
and Hindlimb Bones
To validate and extend our mRNA expression studies, we explored
further if indeed GAS6 protein levels in the humeri were greater than
those in the femora and tibiae at the protein level. Here, immuno-
histochemical staining for GAS6 was performed. We observed that,
indeed GAS6 levels were higher in the humeri versus the femur bones
(Figure 3). Moreover, the staining was localized to the bone surfaces
either at trabeculae or at the endosteal surfaces compared to its expression
in more central marrow locations (Figure 3, A-L). Examination
of GAS6 levels in extracellular marrow supernatants further demon-
strated that the levels of GAS6 in humerus were greater than those
found in the femur (Figure 3M ).
Growth of PCa Cells in a GAS6-Deficient Environment
If GAS6 limits PCa growth, then PCa cells implanted intoGAS6−/−
animals would be expected to result in the growth of larger tumors
Figure 4. Growth of PCa cells in a GAS6-deficient environment. Expression of GAS6 receptors AXL, SKY, and MER in murine RM1 PCa
cells by (A) real-time PCR and (B) FACS. (C) Murine RM1 PCa cells were implanted into GAS6+/+ or GAS6−/− animals, and tumor volume
was measured over time by caliper measurements. Data are presented as mean ± standard deviation from triplicate determinations.
Differences in growth were noted on days 21 and 23 (*P < .05 between paired groups).
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compared to tumors grown in wild-type control animals. To test this,
murine RM1 PCa cells were first evaluated for their expression of the
GAS6 receptors including AXL, SKY, and MER to ensure that GAS6
signaling could occur. Using real-time PCR, AXL expression was sig-
nificantly higher thanMER and SKY, and GAS6 levels were extremely
low (Figure 4A). At the protein level, AXL expression was also signif-
icantly higher than SKY andMER. (Figure 4B). RecentlyGAS6 −/− ani-
mals were generated and made available for experimentation [11].
After validating that these animals do not express GAS6 (Figure 3M),
we used thismodel in conjunctionwith RM1 cells to determinewhether
GAS6 regulates PCa growth in vivo. Critically, when RM1 cells were
implanted into the subcutaneous spaces of immune-competent animals,
tumor growth in theGAS6−/− animals was greater than that inGAS6+/+
control animals (Figure 4C).
Growth of PCa Cells in an Osseous Environment
Devoid of GAS6
Our group has developed an osteogenic assay in which neonatal
skeletal elements from bone in vivo (e.g., vertebral bodies or “vossicles”)
are used to create an ectopic bone marrow environment where bone
niches are generated and can be studied [33]. Here, vossicles from
wild-type or GAS6−/− neonates were seeded with luciferase expressing
cells (PC3luc) and implanted into SCIDmice. Over time, tumor growth
was evaluated by BLI and by measuring tumor volume and weight.
PC3luc cells grew significantly better in vossicles derived from
GAS6 −/− animals compared to tumor cells implanted into vossicles de-
rived from wild-type animals (Figure 5, A-C ). Ki-67– stained tissues
identified more proliferating cells in tumors grown on GAS6−/− vossi-
cles versus GAS6+/+ vossicles (Figure 5D). At the same time, there was
Figure 5. PCa cells grow more rapidly in an osseous environment devoid of GAS6. Paired vossicles from GAS6+/+ or GAS6−/− neonates
were seeded with luciferase-expressing cells (PC3luc) and implanted into the backs of SCIDmice. (A) Over time, the growth of tumors was
evaluated by BLI imaging (left), which was quantified (right). (B) Gross examination of tissues on resection. (C) Tumor volume and weight.
Representative tissue samples immunostained for (D) Ki-67 and (E) TUNEL staining. Data are presented as mean ± standard deviation.
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no significant difference in apoptotic cells in tumor grown in GAS6 −/−
vossicles versus GAS6+/+ vossicles, as determined by TUNEL staining
(Figure 5E ). These observations suggest that the differences in tumor
growth arose mostly from an alteration of proliferation rather than
changes in apoptosis and further suggest that GAS6 limits tumor cell
growth within an osseous environment.
Discussion
The development of PCa disease and its spread to bone remain a major
cause of morbidity and mortality in males. Considerable progress has
been made in early diagnosis, but once the tumor spreads to distant
tissues, survival drastically declines. In 1889, Stephen Paget proposed
a “seed-and-soil” metaphor to explain the marked affinity of cancer
cells for different tissues: “when a plant goes to seed, its seeds are carried
in all directions; but they can only grow if they fall on congenial soil”
[34]. More than a century later, the molecular basis for Paget’s obser-
vations remains unclear. The present work explores the seed-and-soil
hypothesis using an animal model of human PCa bone metastasis.
Collectively, our group has performed many metastatic assays, and
the differences betweenmetastatic lesions found in the forelimbs versus
the hindlimbs are striking. These differences do not seem to depend
on the animal model used. Moreover, the difference seems to be re-
flected in human disease [35–38]. These observations led us to a more
formalized study to determine the molecular basis of the seed and
soil hypothesis.
A possible explanation for the observations that fewer lesions are ob-
served in the arms than in the hindlimb regions of mice is based on car-
diac output to these regions. This view centers on the “hydrodynamic”
or “mechanical” theory that was first proposed by Ewing, which sug-
gested that arterial blood flow was a major determining factor in the fre-
quency of tumor incidence in any given site [39]. Yet surprisingly very
little has been published in the context of cardiac output for the appen-
dicular skeleton of amouse, and even less has been reported in immuno-
deficient animals. What has been reported has been from studies in
rats, where the total cardiac output to the radius, ulna, and humerus
is 0.32% ± 0.19% versus 0.363%± 0.27% for the femur and tibia [40].
If these relationships hold for the mouse, then cardiac output is unlikely
to account for the prevalence of tumors observed in the present study.
Hematogenousmetastases of PCa are known to involve the adhesive
interactions between blood-borne tumor cells and the vessel wall. A
second possibility therefore is that there may be significant differences
in the vasculatures of these regions that permit differential localization
of PCa cells. Previous work with intravital microscopy has shown that
the microvessels in murine bone marrow including the sinusoids and
venules, but not adjacent bone vessels, support rolling interactions of
hematopoietic progenitor cells. However, few if any bone-specific dif-
ferences have been reported [41]. We have shown that PCa cells pref-
erentially bind to bone marrow endothelial cells more than to aortic,
umbilical vein, or dermal vascular endothelial cells [42]. Furthermore,
PCa cells adhere preferentially to bone endothelial cells and not to ex-
tracellular cell matrix proteins present in the bone [43]. Whether these
differences can be translated into specific vascular addresses to account
for our observations in the forelimb versus hindlimb bones remains un-
clear but seems doubtful because the differences in metastatic lesions
are not reflected in the number of PCa cells that actually arrive in the
marrow 24 hours after injection [42,44].Moreover, the possibility that
tumor prevalence reflects differences in the number of available HSC
niches in the humerus versus the femur and tibia seems unlikely. Re-
cently, we demonstrated that disseminated PCa cells directly compete
with HSCs for occupancy of the HSC niche and that increasing/
decreasing niche size alters dissemination [9]. Although there is no di-
rect method to assess the number of niches present in any tissue, the
number of HSCs did not differ significantly between the forelimb
and hindlimbs.
Another mechanism that may explain the differences in metastatic
prevalence between the forelimb versus hindlimb bones is that a factor
exists in the bone marrow microenvironment of the hindlimb bones
that stimulates growth of the PCa cells compared to the forelimb
bones. Conversely, the levels of a suppressive growth factor may be rel-
atively high in the bones of the forelimb versus the hindlimb bones.
Our search for a stimulatory factor resulted in the identification of
Figure 5. (continued).
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no factor, which was differentially expressed in the hindlimb versus the
forelimb bones (Pienta et al., unpublished observations). Recently, we
showed that GAS6, the ligand for the AXL family RTKs, enhances in-
vasion, inhibits proliferation, prevents apoptosis induced by chemo-
therapy, and alters cell cycling state of PCa cells [31]. In addition,
we demonstrated that activation of AXL by GAS6 on PCa cells in a
bone marrow niche environment plays a critical role as a molecular
switch to establish dormancy of PCa cells [31]. Surprisingly, we noted
that the levels of GAS6mRNA and protein were significantly higher in
the forelimb versus hindlimb bones. The reason for this is not clear;
however, subcutaneous and intraosseous studies in a GAS6-deficient
animal model strongly suggest that GAS6 does limit tumor growth.
The role of GAS6 in PCa is controversial and may reflect activities
that are dose and cell maturation dependent, as has been shown for
several other ligands including TGF-β1 and PTHrP. Previous reports
suggest that GAS6 may be a stimulator of PCa growth [45]. We
have made several attempts to replicate these data without success
[31], and our more recent in vivo data are consistent with a role for
GAS6 in limiting PCa growth. However, it is important to keep in
mind that the activity of GAS6 is highly dependent on glycosylation
and on the cellular context in which the cells find themselves [45,46].
Importantly, there is indeed precedence linking GAS6 or its receptors
to tumor promotion [47–50]. It is also important to recognize that the
effects of regulatory molecules are often organ and/or dose dependent.
For example, parathyroid hormone, although classically reported to be
a bone-resorbing hormone, also has anabolic actions in bone by signal-
ing through the same receptor [5]. Likewise, GAS6 may well have
growth inhibitory and stimulatory activities in PCa. Further studies
using similar models, dosing and protocols are needed before drawing
definitive conclusions as to the ultimate effects of GAS6 on skeletal
metastases in vivo.
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